相关实验视频

Updated: Mar 8, 2026

Acupoint Catgut Embedding Therapy in Traditional Chinese Medicine for Managing Allergic Rhinitis

Acupoint Catgut Embedding Therapy in Traditional Chinese Medicine for Managing Allergic Rhinitis

Published on: December 20, 2024

特兰胺酸用于治疗ACE抑制剂诱导的血管:一个比较结果分析

Karalynn Otterness¹, Melanie Keister¹, Jonathan Zhu¹

¹Department of Emergency Medicine, Renaissance School of Medicine at Stony Brook University, Stony Brook, NY 11794, United States of America.

The American journal of emergency medicine

|March 6, 2026

概括

在患有血管激素转化酶抑制剂 (ACEI) 诱导的血管腺的患者中,胺酸 (TXA) 并没有降低30天死亡率. 使用TXA与增加ICU入院和呼吸道干预相关,质疑其常规应用.

科学领域:

心脏病学心脏病学
肺部病理学肺部病理学
药理学药理学是指药理学的学科.

背景情况:

ангиотензин转化酶抑制剂 (ACEI) 诱导的血管是一种严重的药物不良反应.
这种情况可能导致呼吸道受损,并需要住院治疗.
胺酸 (TXA) 是一种潜在的治疗方法,但其相对有效性尚未得到充分证实.

研究的目的:

调查TXA给药与ACEI诱导的血管患者30天死亡率之间的关联.
评估二次结果,包括静脉血栓塞栓症 (VTE),ICU入院,呼吸道干预和住院.

主要方法:

使用 TriNetX 全球健康研究网络进行的回顾性队列研究.
包括20787名被诊断患有ACEI诱导的血管的成年患者.
根据20个特征,对1080名TXA用户和19707名非用户进行了倾向分数匹配 (1:1).

主要成果:

在TXA和无TXA组之间30天死亡率没有显著差异 (1.0%对0.9%).
使用TXA与显著更高的ICU入院率 (24.8%对11.9%),呼吸道干预 (7.8%对5.1%) 和入院率 (35.8%对27.3%) 相关.
静脉血栓栓塞 (VTE) 发生率较低,在各组之间相似.

结论:

在ACEI诱导的血管中,TXA的使用与30天死亡率的降低无关.
使用TXA与增加ICU入院和呼吸道干预相关.
目前的证据不支持在ACEI诱导的血管中常规使用TXA;需要对高风险人群进行进一步的研究.

关键词:

由ACE抑制剂诱导的血管功能.特兰克萨姆酸是什么意思血管发炎血管发炎

更多相关视频

Author Spotlight: Non-Surgical Treatment of Melasma– Microneedling with Tranexamic Acid

Author Spotlight: Non-Surgical Treatment of Melasma– Microneedling with Tranexamic Acid

Published on: January 19, 2024

Continuous IV Infusion is the Choice Treatment Route for Arginine-vasopressin Receptor Blocker Conivaptan in Mice to Study Stroke-evoked Brain Edema

Continuous IV Infusion is the Choice Treatment Route for Arginine-vasopressin Receptor Blocker Conivaptan in Mice to Study Stroke-evoked Brain Edema

Published on: September 1, 2016

相关概念视频

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors

Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...

Antihypertensive Drugs: Direct Renin Inhibitors

Antihypertensive Drugs: Direct Renin Inhibitors

The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...

Antianginal Drugs: Nitrates and β-Blockers

Antianginal Drugs: Nitrates and β-Blockers

In cardiovascular health, antianginal drugs combat angina pectoris — a condition marked by chest pain owing to diminished blood flow to the heart.
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow....

Angina IV: Management

Angina IV: Management

IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...